{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:04:19Z","timestamp":1792109059649,"version":"4.4.0"},"reference-count":101,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003336","name":"Bulgarian National Science Fund","doi-asserted-by":"crossref","award":["BG-RRP-2.004-0004-C01"],"award-info":[{"award-number":["BG-RRP-2.004-0004-C01"]}],"id":[{"id":"10.13039\/501100003336","id-type":"DOI","asserted-by":"crossref"}]},{"award":["BG-RRP-2.004-0004-C01"],"award-info":[{"award-number":["BG-RRP-2.004-0004-C01"]}],"id":[{"id":"https:\/\/ror.org\/05eg49r29","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Bulgarian National Plan for Recovery and Resilience"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) and influenza share key pathogenic mechanisms, including viral invasion, dysregulated innate immune activation, and the development of severe systemic complications. A central mediator of disease progression in both infections is the hyperactivation of the NLRP3 inflammasome, which drives excessive production of pro-inflammatory cytokines, immunothrombosis, multiorgan injury, and increased mortality. Colchicine possesses a unique pharmacokinetic property of preferential accumulation within myeloid cells, where sufficiently high intracellular concentrations inhibit NLRP3 inflammasome activation. This mechanism provides a biological rationale for preventing the cytokine storm and its downstream consequences when colchicine is administered early during infection. Available pharmacokinetic, toxicological, and clinical evidence suggests that loading doses of colchicine up to approximately 0.05 mg\/kg body weight can be administered safely in appropriately selected patients, provided that clinically significant drug\u2013drug interactions and hepatic or renal impairment are carefully excluded. The widely accepted belief that total doses of 7\u20137.5 mg are inherently lethal appears to reflect historical cases complicated by drug interactions and\/or hepatic or renal impairment, rather than toxicity attributable to colchicine dose alone. These observations support reconsideration of current guideline recommendations regarding colchicine dosing. In particular, cumulative doses below 0.1 mg\/kg appear to be consistently safe, whereas doses between 0.1 and 0.2 mg\/kg are associated with only a low risk of toxicity and rarely with severe intoxication. Reassessment of colchicine dosing strategies may therefore be warranted to optimize NLRP3 inflammasome inhibition and improve outcomes in patients with COVID-19 and influenza.<\/jats:p>","DOI":"10.3390\/ijms27156827","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:09:42Z","timestamp":1785398982000},"page":"6827","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7528-590X","authenticated-orcid":false,"given":"Vanyo","family":"Mitev","sequence":"first","affiliation":[{"name":"Research Institute of Innovative Medical Science, Medical University Sofia, Akad. Ivan Geshov 15, 1431 Sofia, Bulgaria"},{"name":"Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University Sofia, Akad. Ivan Geshov 15, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long Covid: Major Findings, Mechanisms and Recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","first-page":"02","article-title":"Long Covid in Adults\u2014A Current Review of the Long-Term Health Effects Following SARS-CoV-2 Infection","volume":"11","author":"Beyer","year":"2026","journal-title":"J. Health Monit."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/eurpub\/ckae098","article-title":"The 100 Most-Cited Articles in COVID-19: A Bibliometric Analysis","volume":"34","author":"Liew","year":"2024","journal-title":"Eur. J. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"111705","DOI":"10.1016\/j.jclinepi.2025.111705","article-title":"Massive Covidization and Subsequent Decovidization of the Scientific Literature Involved 2 Million Authors","volume":"180","author":"Ioannidis","year":"2025","journal-title":"J. Clin. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/17407745251400635","article-title":"Topic-Specific Living Databases of Clinical Trials: A Scoping Review of Public Databases","volume":"23","author":"Boesen","year":"2026","journal-title":"Clin. Trials"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"World Health Organization (2025). WHO Communicable Diseases Therapeutics and COVID-19: Living Guideline, August 2025, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/b09540.","DOI":"10.2471\/B09540"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"The RECOVERY Collaborative Group (2020). Dexamethasone in Hospitalized Patients with COVID-19\u2014Preliminary Report. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_8","unstructured":"World Health Organization (2025). Coronavirus Disease (COVID-19) Fact Sheet, Therapeutics and COVID-19: Living Guideline, August 2025, World Health Organization."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa2502457","article-title":"Oral Nirmatrelvir\u2013Ritonavir for COVID-19 in Higher-Risk Outpatients","volume":"394","author":"Butler","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3897\/pharmacia.70.e112550","article-title":"Comparison of Treatment of COVID-19 with Inhaled Bromhexine, Higher Doses of Colchicine and Hymecromone with Who-Recommended Paxlovid, Molnupiravir, Remdesivir, Anti-IL-6 Receptor Antibodies and Baricitinib","volume":"70","author":"Mitev","year":"2023","journal-title":"Pharmacia\/Farmaci\u00e2"},{"key":"ref_11","unstructured":"World Health Organization: WHO (2026, July 22). Who Updates Its Treatment Guidelines to Include Molnupiravir. Available online: https:\/\/www.who.int\/news\/item\/03-03-2022-molnupiravir."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium (2020). Repurposed Antiviral Drugs for COVID-19\u2014Interim Who Solidarity Trial Results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_13","unstructured":"RECOVERY Collaborative Group (2021). Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomized, Controlled, Open-Label, Platform Trial. Lancet, 397, 1637\u20131645."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.abm8108","article-title":"The Immunology and Immunopathology of COVID-19","volume":"375","author":"Merad","year":"2022","journal-title":"Science"},{"key":"ref_15","first-page":"e30269","article-title":"Complete, Rapid Resolution of Severe Bilateral Pneumonia and Acute Respiratory Distress Syndrome in a COVID-19 Patient: Role for a Unique Therapeutic Combination of Inhalations with Bromhexine, Higher Doses of Colchicine, and Hymecromone","volume":"14","author":"Mondeshki","year":"2022","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e59177","DOI":"10.7554\/eLife.59177","article-title":"A Mechanistic Model and Therapeutic Interventions for COVID-19 Involving a Ras-Mediated Bradykinin Storm","volume":"9","author":"Garvin","year":"2020","journal-title":"eLife"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3892\/mmr.2022.12867","article-title":"Role of Endothelial Dysfunction in the Severity of COVID-19 Infection (Review)","volume":"26","author":"Kadiyska","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e02609-24","DOI":"10.1128\/mbio.02609-24","article-title":"Hyaluronan in COVID-19: A Matrix for Understanding Lung Disease","volume":"15","author":"Dodd","year":"2024","journal-title":"mBio"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15418","DOI":"10.1074\/jbc.AC120.015967","article-title":"Presence of Hyaluronan in Lung Alveoli in Severe COVID-19: An Opening for New Treatment Options?","volume":"295","author":"Hellman","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.thromres.2018.01.046","article-title":"Effectiveness and Safety of Outpatient Rivaroxaban versus Warfarin for Treatment of Venous Thromboembolism in Patients with a Known Primary Hypercoagulable State","volume":"163","author":"Coleman","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil Extracellular Traps Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial Dysfunction and Immunothrombosis as Key Pathogenic Mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e57555","DOI":"10.7554\/eLife.57555","article-title":"Kallikrein-Kinin Blockade in Patients with COVID-19 to Prevent Acute Respiratory Distress Syndrome","volume":"9","author":"Netea","year":"2020","journal-title":"eLife"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome Activation at the Crux of Severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41577-024-00995-w","article-title":"Mechanistic Insights from Inflammasome Structures","volume":"24","author":"Fu","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.jbc.2022.102717","article-title":"The Leucine-Rich Repeat (LRR) Domain of NLRP3 Is Required for NLRP3 Inflammasome Activation in Macrophages","volume":"298","author":"Duan","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41423-022-00922-w","article-title":"How Location and Cellular Signaling Combine to Activate the NLRP3 Inflammasome","volume":"19","author":"Akbal","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.54963\/ti.v9i3.1162","article-title":"Prevention and Treatment of COVID-19 and Influenza with Bromhexine and High Doses of Colchicine","volume":"9","author":"Mitev","year":"2025","journal-title":"Trends Immunother."},{"key":"ref_32","first-page":"43","article-title":"Drugging the NLRP3 Inflammasome: From Signalling Mechanisms to Therapeutic Targets","volume":"23","author":"Lamkanfi","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","article-title":"Fc\u03b3R-Mediated SARS-CoV-2 Infection of Monocytes Activates Inflammation","volume":"606","author":"Junqueira","year":"2022","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gardner, J., and Herbst-Kralovetz, M. (2016). Three-Dimensional Rotating Wall Vessel-Derived Cell Culture Models for Studying Virus-Host Interactions. Viruses, 8.","DOI":"10.3390\/v8110304"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e20201707","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes Are Activated in Response to SARS-CoV-2 Infection and Are Associated with COVID-19 Severity in Patients","volume":"218","author":"Rodrigues","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41420-021-00428-w","article-title":"SARS-CoV-2 Engages Inflammasome and Pyroptosis in Human Primary Monocytes","volume":"7","author":"Ferreira","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-021-25015-6","article-title":"SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation","volume":"12","author":"Pan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41385-020-00359-2","article-title":"The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection","volume":"14","author":"Gallo","year":"2021","journal-title":"Mucosal Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Barros, G., Nencioni, E., Thimoteo, F., Perea, C., Fuzaro, R., and Sasaki, S.D. (2025). Tmprss2 as a Key Player in Viral Pathogenesis: Influenza and Coronaviruses. Biomolecules, 15.","DOI":"10.3390\/biom15010075"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/qjmed\/hcad011","article-title":"NLRP3, the Inflammasome and COVID-19 Infection","volume":"116","author":"Yin","year":"2023","journal-title":"QJM Int. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1111\/bph.15229","article-title":"The Hidden Role of NLRP3 Inflammasome in Obesity-Related COVID-19 Exacerbations: Lessons for Drug Repurposing","volume":"177","author":"Bertocchi","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104299","DOI":"10.1016\/j.ebiom.2022.104299","article-title":"Interleukin-1 and the NLRP3 Inflammasome in COVID-19: Pathogenetic and Therapeutic Implications","volume":"85","author":"Potere","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.matbio.2018.06.006","article-title":"Defective Lung Function Following Influenza Virus Is Due to Prolonged, Reversible Hyaluronan Synthesis","volume":"80","author":"Bell","year":"2019","journal-title":"Matrix Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","article-title":"COVID-19: The Vasculature Unleashed","volume":"20","author":"Teuwen","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41579-021-00542-7","article-title":"Influenza Virus and SARS-CoV-2: Pathogenesis and Host Responses in the Respiratory Tract","volume":"19","author":"Flerlage","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Freeman, T.L., and Swartz, T.H. (2020). Targeting the NLRP3 Inflammasome in Severe COVID-19. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01518"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mitev, V. (2024). Colchicine\u2014The Divine Medicine against COVID-19. J. Pers. Med., 14.","DOI":"10.20944\/preprints202406.0822.v1"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mitev, V., and Momekov, G. (2025). Colchicine Only Inhibits in Higher Doses Hyperactivated NLRP3 Inflammasome\u2014The Main Respondent for Complications in COVID-19 and Influenza. Front. Biosci.-Landmark, 30.","DOI":"10.31083\/FBL44744"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3897\/pharmacia.72.e162569","article-title":"High Colchicine Doses Are More Effective in COVID-19 Outpatients than Nirmatrelvir\/Ritonavir, Remdesivir, and Molnupiravir","volume":"72","author":"Mitev","year":"2025","journal-title":"Pharmacia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/annrheumdis-2020-219174","article-title":"Anti-Inflammatory Therapy for COVID-19 Infection: The Case for Colchicine","volume":"80","author":"Reyes","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","first-page":"e54441","article-title":"High Doses of Colchicine Act as \u201cSilver Bullets\u201d against Severe COVID-19","volume":"16","author":"Lilov","year":"2024","journal-title":"Cureus"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial Cell Infection and Endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1128\/JVI.03544-13","article-title":"Roles of Humidity and Temperature in Shaping Influenza Seasonality","volume":"88","author":"Lowen","year":"2014","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural Mechanism for NEK7-Licensed Activation of NLRP3 Inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014Update on Mechanisms of Action and Therapeutic Uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 Inflammasome in Inflammatory Diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tengesdal, I.W., Banks, M., Dinarello, C.A., and Marchetti, C. (2024). Screening Nlrp3 Drug Candidates in Clinical Development: Lessons from Existing and Emerging Technologies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1422249"},{"key":"ref_58","first-page":"e58164","article-title":"High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients","volume":"16","author":"Mondeshki","year":"2024","journal-title":"Cureus"},{"key":"ref_59","first-page":"e63201","article-title":"Successful Treatment with High-Dose Colchicine of a 101-Year-Old Patient Diagnosed with COVID-19 after an Emergency Cholecystectomy","volume":"16","author":"Bulanov","year":"2024","journal-title":"Cureus"},{"key":"ref_60","first-page":"1","article-title":"Effects of Long-Term Prophylaxis with Bromhexine Hydrochloride and Treatment with High Colchicine Doses of COVID-19","volume":"72","author":"Marinov","year":"2025","journal-title":"Pharmacia"},{"key":"ref_61","first-page":"e35909","article-title":"Effect of an Accidental Colchicine Overdose in a COVID-19 Inpatient with Bilateral Pneumonia and Pericardial Effusion","volume":"15","author":"Mondeshki","year":"2023","journal-title":"Cureus"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mitev, V., Mondeshki, T., Marinov, K., and Bilukov, R. (2023). Colchicine, Bromhexine, and Hymecromone as Part of COVID-19 Treatment-Cold, Warm, Hot. Current Overview on Disease and Health Research Vol. 10, B P International (a part of SCIENCEDOMAIN International).","DOI":"10.9734\/bpi\/codhr\/v10\/5310A"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e1273","DOI":"10.1002\/iid3.1273","article-title":"Effect of Increasing Doses of Colchicine on the Treatment of 333 COVID-19 Inpatients","volume":"12","author":"Tiholov","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_64","first-page":"101009","article-title":"Investigating the Effectiveness of Colchicine Tablets on the Outcomes of Mechanically Ventilated Patients with COVID-19: A Randomized Clinical Trial","volume":"24","author":"Ghorbani","year":"2026","journal-title":"Int. J. Afr. Nurs. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2129006","DOI":"10.1155\/2021\/2129006","article-title":"Efficacy of Colchicine and Budesonide in Improvement Outcomes of Patients with Coronavirus Infection 2019 in Damascus, Syria: A Randomized Control Trial","volume":"2021","author":"Alsultan","year":"2021","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019","volume":"3","author":"Deftereos","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e001455","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial Effects of Colchicine for Moderate to Severe COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial","volume":"7","author":"Lopes","year":"2021","journal-title":"RMD Open"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/11101849.2022.2089518","article-title":"Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients","volume":"38","author":"Haggag","year":"2022","journal-title":"Egypt. J. Anaesth."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e074373","DOI":"10.1136\/bmjopen-2023-074373","article-title":"Colchicine for the Treatment of Patients with COVID-19: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"14","author":"Cheema","year":"2024","journal-title":"BMJ Open"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group (2021). Colchicine Inpatient Trial. Lancet Respir. Med., 9, 1419\u20131426.","DOI":"10.1016\/S2213-2600(21)00435-5"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2288240","DOI":"10.1080\/13102818.2023.2288240","article-title":"What Is the Lowest Lethal Dose of Colchicine?","volume":"37","author":"Mitev","year":"2023","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/archdischild-2025-328646","article-title":"Paediatric Colchicine Poisoning in the UK: A 10-year Retrospective Case Series from the National Poisons Information Service","volume":"111","author":"Kazi","year":"2026","journal-title":"Arch. Dis. Child."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/ard.6.4.224","article-title":"Hypersensitivity to Colchicine","volume":"6","author":"Macleod","year":"1947","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine Poisoning: The Dark Side of an Ancient Drug","volume":"48","author":"Finkelstein","year":"2010","journal-title":"Clin. Toxicol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0196-0644(81)80239-9","article-title":"Overdose Cases: Report of Two Cases and Review of the Literature","volume":"10","author":"Stapczynski","year":"1981","journal-title":"Ann. Emerg. Med."},{"key":"ref_76","first-page":"1625","article-title":"Aplasie Medullaire Apres Intoxication Aigue a La Colchicine","volume":"6","author":"Bismuth","year":"1977","journal-title":"Nouv. Presse Med."},{"key":"ref_77","first-page":"U2402","article-title":"Colchicine Overdose: The Devil Is in the Detail","volume":"120","author":"Jayaprakash","year":"2007","journal-title":"N. Z. Med. J."},{"key":"ref_78","first-page":"1","article-title":"Early Whole Bowel Irrigation to Treat Colchicine Overdose: A Brief Review of 30 Years of Decontamination Strategies","volume":"16","author":"Mahmud","year":"2025","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s11739-022-03079-6","article-title":"Progress in the Management of Acute Colchicine Poisoning in Adults","volume":"17","author":"Wu","year":"2022","journal-title":"Intern. Emerg. Med."},{"key":"ref_80","first-page":"e53","article-title":"Clinical Manifestations and Outcomes of Colchicine Poisoning Cases: A Cross-Sectional Study","volume":"8","author":"Rahimi","year":"2020","journal-title":"Arch. Acad. Emerg. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e16580","DOI":"10.1097\/MD.0000000000016580","article-title":"Clinical Outcomes after Colchicine Overdose","volume":"98","author":"Fu","year":"2019","journal-title":"Medicine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/1556-4029.15298","article-title":"Delayed Elimination in Humans after Ingestion of Colchicine: Two Fatal Cases of Colchicine Poisoning","volume":"68","author":"Deng","year":"2023","journal-title":"J. Forensic Sci."},{"key":"ref_83","first-page":"e19151","article-title":"Severe Colchicine Intoxication: A Case Report and Review of Literature in Adults","volume":"13","author":"Seixas","year":"2021","journal-title":"Cureus"},{"key":"ref_84","first-page":"612","article-title":"Death Following Colchicine Poisoning: A Case Report","volume":"15","author":"Kim","year":"2026","journal-title":"J. Korean Soc. Emerg. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/PAF.0000000000000757","article-title":"A Fatal Colchicine Ingestion with Antemortem Blood Concentration","volume":"43","author":"McCabe","year":"2022","journal-title":"Am. J. Forensic Med. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_87","first-page":"680","article-title":"Waterhouse\u2013Friderichsen Syndrome Resulting from Colchicine Overdose","volume":"86","author":"Stringfellow","year":"1993","journal-title":"J. R. Soc. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2141.2009.07581.x","article-title":"Haematological Toxicity of Colchicine","volume":"146","author":"Dickinson","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2133.2004.05838.x","article-title":"Toxic Epidermal Necrolysis-Like Reaction Secondary to Colchicine Overdose","volume":"150","author":"Arroyo","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1442-2026.1998.tb00674.x","article-title":"Colchicine Poisoning\u2014Overview and New Directions","volume":"10","author":"Harris","year":"1998","journal-title":"Emerg. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00000441-197907000-00009","article-title":"Fatal Colchicine Poisoning in a Boy with Familial Mediterranean Fever","volume":"278","author":"Stahl","year":"1979","journal-title":"Am. J. Med. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0310057X8601400422","article-title":"A Fatal Colchicine Overdose","volume":"14","author":"Hobson","year":"1986","journal-title":"Anaesth. Intensive Care"},{"key":"ref_93","first-page":"136","article-title":"Neutrophilic Leukocyte Inclusions in Colchicine Intoxication","volume":"100","author":"Powell","year":"1976","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/0003-4819-83-4-523","article-title":"Adult Respiratory Distress Syndrome Associated with Colchicine Intoxication","volume":"83","author":"Hill","year":"1975","journal-title":"Ann. Intern. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/15563657909010599","article-title":"Estimation of Colchicine in a Poisoned Patient by Using High Performance Liquid Chromatography","volume":"14","author":"Jarvie","year":"1979","journal-title":"Clin. Toxicol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine Today","volume":"73","author":"Niel","year":"2006","journal-title":"Jt. Bone Spine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus Low Dosing of Oral Colchicine for Early Acute Gout Flare: Twenty-Four-Hour Outcome of the First Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Colchicine Study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does Colchicine Work? The Results of the First Controlled Study in Acute GOUT","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust. N. Z. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e70438","DOI":"10.1002\/iid3.70438","article-title":"COVID-19 Prophylactic Effect of Bromhexine Hydrochloride","volume":"14","author":"Mitev","year":"2026","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.4103\/jfmpc.jfmpc_185_26","article-title":"Pilot Survey Among Patients Taking Bromhexine Prophylactically Against Influenza","volume":"15","author":"Mitev","year":"2026","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_101","first-page":"1","article-title":"Pharmacoeconomic Analysis of Bromhexine for Prophylactic of Influenza A and B","volume":"73","author":"Petrova","year":"2026","journal-title":"Pharmacia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6827\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:24:01Z","timestamp":1785558241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":101,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156827"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156827","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}